INTRODUCTION {#s1}
============

Stroke is thought to be the main cause of death and disability-adjusted life-years lost globally \[[@R1]\]. Especially in recent years, we are confronted with the severe consequences caused by stroke \[[@R1], [@R2]\]. The first proven medical treatment of acute ischemic stroke (AIS) is intravenous thrombolysis with tissue plasminogen activator (t-PA) \[[@R3]\]. The recanalization rate of intravenous thrombolysis is not ideal in major large vessel occlusion \[[@R4]\]. Moreover, only limited patients are eligible for the therapy of t-PA because of the transient therapeutic time window (\< 4.5 hours) \[[@R5]\] and other strict qualified criteria for administration (a history of intracranial hemorrhage, coagulation abnormalities, recent surgery) \[[@R6], [@R7]\].

In order to improve the recanalization rate, endovascular treatment (EVT) which includes mechanical thrombectomy and intra-arterial t-PA, has appeared as the alternative treatment for several years \[[@R8]\]. First generation thrombectomy techniques involve a thrombus aspiration by coil retrievers. With the improvement of endovascular techniques, the second generation device (Solitaire flow restoration device) could be placed within the thrombus and extract the clot as the stent is withdrawn \[[@R9]\]. Compared with medical therapy alone, mechanical thrombectomy can significantly increase the recanalization rate of large artery occlusion with Solitaire flow restoration device (Solitaire FR) \[[@R10], [@R11]\]. This is thought to be the crucial factor of favorable functional outcomes in ischemic stroke patients \[[@R12]\]. In theory, the use of mechanical thrombectomy combined with intravenous t-PA should express their respective advantages including favorable recanalization rate and quick administration \[[@R13]\]. However, the functional outcomes of four randomized control trials (IMS III \[[@R14]\], MR RESCUE \[[@R15]\], SYNTHESIS \[[@R8]\], THERAPY \[[@R16]\]) showed no significant difference between EVT and medical therapy. It may be attributed to the reasons that intra-arterial t-PA or first-generation mechanical thrombectomy devices played a primary role in EVT, patients were enrolled without imaging evidence of large vessel occlusion and the irregular use of IV t-PA in EVT group. On the contrary, EVT showed its overwhelming advantages in both favorable functional outcomes and recanalization rate in RCTs after 2015 (THRACE \[[@R13]\], EXTEND-IA \[[@R17]\], MR CLEAN \[[@R18]\], SWIFT PRIME \[[@R19]\], REVASCAT \[[@R20]\], ESCAPE \[[@R21]\], PISTE \[[@R22]\]). These RCTs improved the above-mentioned limitations by enrolling patients with the confirmation of large vessel occlusion, regular use of IV t-PA, and a higher rate of using thrombectomy devices in EVT group. The different results of diverse RCTs have aroused great interest of researchers. Continuous RCTs and meta-analysis were performed to assess the effectiveness of EVT and the relative influence factors \[[@R4], [@R23], [@R24]\].

Previous meta-analysis used pre-specified subgroups to find out the possible reasons of heterogeneity in functional outcomes between different therapies. This approach may lead to the neglect of potential important factors \[[@R4], [@R23], [@R24]\]. Hence, we pooled data from eleven eligible multicenter RCTs to explore the efficacy and safety of EVT for AIS. Simultaneously, a mathematical method would be implemented to observe all the possible factors that might affect therapy outcome without undue man-made interference.

RESULTS {#s2}
=======

Search results and study characteristics {#s2_1}
----------------------------------------

This search strategy gathered 828 studies from PubMed, Web of Science, Cochrane Central Register of Controlled Trials (Figure [1](#F1){ref-type="fig"}). 752 studies were excluded after the screening because the titles and abstracts did not qualified. Then, 30 studies were assessed for eligibility, and 19 articles were excluded for the following reasons: 1 protocol, 3 not randomized controlled trials, 4 no mechanical thrombectomy group, 11 duplicate articles or data. The data were extracted from 11 RCTs: IMS III \[[@R14]\], MR RESCUE \[[@R15]\], SYNTHESIS \[[@R8]\], THRACE \[[@R13]\], EXTEND-IA \[[@R17]\], MR CLEAN \[[@R18]\], SWIFT PRIME \[[@R19]\], REVASCAT \[[@R20]\], ESCAPE \[[@R21]\], PISTE \[[@R22]\], THERAPY \[[@R16]\].

![Search and selection process](oncotarget-08-72972-g001){#F1}

In these 11 studies (Table [1](#T1){ref-type="table"}), the number of participants ranged from 65 to 656. All of these studies involved mechanical thrombectomy with t-PA as a part of the EVT, except the SYNTHESIS \[[@R8]\]. Patients in the EVT group were treated with different thrombectomy devices. In three RCTs (IMS III \[[@R14]\], MR RESCUE \[[@R15]\], SYNTHESIS \[[@R8]\]), patients were included without imaging confirmation of large vessel occlusion at the initial stage of the trials. The detailed data of study characteristics are shown in Table [1](#T1){ref-type="table"}.

###### Characteristics of studies included in the meta-analysis

  Trials              No. of centers   Location                             No. of patients   Devices                                                                    No. of IV t-PA(%)   Age     Time frame (h)   NIHSS    confirmation of large vessel occlusion            
  ------------------- ---------------- ------------------------------------ ----------------- -------------------------------------------------------------------------- ------------------- ------- ---------------- -------- ---------------------------------------- -------- ------
  IMS III, 2013       58               North America, Europe, Australia     656               Merci Retriever, Penumbra System, Solitaire FR Device, Micro Sonic         100%                100%    18--82           3        5                                        ≥ 10     NO\*
  MR RESCUE, 2013     22               North America                        127               Merci Retriever, Penumbra System                                           29.6%               43.8%   18--85           4.5      8                                        29-Jun   NO\*
  SYNTHESIS, 2013     24               Italy                                362               Solitaire FR Device, Penumbra System, Trevo device, Merci Retriever        96.1%               0       18--80           4.5      6                                        ≤ 25     NO\*
  EXTEND-IA, 2015     14               Australia, New Zealand               70                Solitaire FR Device                                                        100%                100%    ≥ 18             4.5      6                                        \_\_     YES
  MR CLEAN, 2015      16               Netherlands                          500               Solitaire FR Device, Merci retriever, Thromboaspiration, Wire disruption   90.6%               87.1%   ≥ 18             4.5      6                                        ≥2       YES
  SWIFT PRIME, 2015   39               America, Europe                      196               Solitaire FR or Solitaire 2                                                100%                100%    18--80           4.5      6                                        29-Aug   YES
  REVASCAT, 2015      4                Spain                                206               Solitaire FR                                                               77.7%               68%     18--85           4.5      8                                        ≥ 6      YES
  ESCAPE, 2015        22               North America, Europe, South Korea   315               Solitaire FR,Thromboaspiration,                                            78.7%               72.7%   ≥ 18             4.5      12                                       ≥ 5      YES
  THRACE, 2016        26               France                               412               Solitaire, Penumbra, Trevo                                                 100%                100%    18--80           4        5                                        25-Oct   YES
  PISTE, 2017         10               United Kingdom                       65                Stent-retriever, Aspiration                                                100%                100%    ≥ 18             4.5      6                                        ≥ 6      YES
  THERAPY, 2016       36               US, German                           108               Penumbra System, Solitaire FR, Trevo                                       100%                100%    18--85           3--4.5   8                                        ≥ 8      YES

NIHSS: National Institutes of Health Stroke Scale; t-PA: intravenous thrombolysis with tissue plasminogen activator; EVT: endovascular treatment.

\*At the beginning of the trials, patients were included without imaging confirmation of large vessel occlusion.

Clinical outcomes {#s2_2}
-----------------

### Primary outcomes {#s2_2_1}

In this meta-analysis, patients treated with EVT showed a higher proportion of favorable functional outcome at 90 days (OR, 1.71; 95% CI, 1.28--2.28; *P* \< 0.001; Figure [2A](#F2){ref-type="fig"}) than those treated with standard medical therapy. There was moderate heterogeneity (*I*^2^ = 65.7%, *P* = 0.001) among the included RCTs.

![The pooled odd ratio of primary outcomes and secondary outcomes\
(**A**) mRS 0--2 at 90days, (**B**) all-cause mortality at 90 days, (**C**) recanalization rate at 24 h, (**D**) systematic intracranial hemorrhage (\*: Systematic intracranial hemorrhage at 7 days in THRACE 2016. \*\*: PISTE 2017 was excluded because that the incidence of sICH was zero).](oncotarget-08-72972-g002){#F2}

Secondary outcomes {#s2_3}
------------------

Mortality at 90 days showed no significant difference in all-cause mortality at 90 days between EVT and standard medical therapy (OR, 0.86; 95% CI, 0.69--1.07; *P* = 0.165; Figure [2B](#F2){ref-type="fig"}). Four trials reported the revascularization rate at 24h in both EVT and standard medical therapy groups. EVT group had a better recanalization rate compared to the standard medical therapy group (OR, 6.49; 95% CI, 4.79--8.79; *P* \< 0.001; Figure [2C](#F2){ref-type="fig"}). No significant difference was found in the incidence of sICH following EVT compared to standard medical therapy (OR, 1.10; 95% CI, 0.78--1.55; *P* = 0.584; Figure [2D](#F2){ref-type="fig"}).

Meta regression and subgroup {#s2_4}
----------------------------

Moderate heterogeneity was observed among the 11 RCTs regarding favorable functional outcomes (*I*^2^ = 65.7%, *P* \< 0.001). Hence, we conducted a univariate meta-regression regression analysis to find out the potential influencing factors. In the meta-regression, the rate of using solitaire FR could explain 72.21% of heterogeneity (*P* = 0.014, Adj R-squared = 72.21%; Table [2](#T2){ref-type="table"}). In addition, hyperlipidemia and atrial fibrillation could respectively explain 35.21% (*P* = 0.159, Adj R-squared = 35.21%; Table [2](#T2){ref-type="table"}) and 46.30% (*P* = 0.054, Adj R-squared = 46.30%; Table [2](#T2){ref-type="table"}) of heterogeneity. In order to define the impact of these factors, we stratified the trials into low and high percentage of patients with corresponding characteristics (Figure [3](#F3){ref-type="fig"} and Figure [4](#F4){ref-type="fig"}). In subgroup analysis, patients with the high use rate (\> = 60%) of solitaire FR in EVT arm had favorable functional outcomes compared with standard medical care alone (OR, 2.14; 95% CI, 1.75--2.61; *P* \< 0.001; Figure [3A](#F3){ref-type="fig"}). Meanwhile, in subgroups with the high percentage (\> = 35%) of patients with atrial fibrillation, EVT also demonstrated an improving tendency in favorable functional outcomes (OR, 2.40; 95% CI, 1.81--3.19; *P* \< 0.001; Figure [3C](#F3){ref-type="fig"}). Similar outcomes were also shown in subgroups with a low rate (\< 50%) of patients with hyperlipidemia (OR, 2.34; 95% CI, 1.80--3.04; *P* \< 0.001; Figure [3B](#F3){ref-type="fig"}).

###### Single factor regression of the potential influence factors

  Covariates             No. of RCTs   *P* value   Adj R-squared   coefficients   95%CI
  ---------------------- ------------- ----------- --------------- -------------- ----------------------
  Age                    11            0.129       22.16%          0.089393       −0.03156 0.2103455
  Male                   11            0.315       6.89%           −3.61211       −11.29812 4.073904
  Hypertension           11            0.58        −14.47%         −0.87801       −4.334825 2.578802
  Diabetes               11            0.796       −12.49%         0.640172       −4.785959 6.066303
  History of stroke      8             0.515       −199.06%        −2.25503       −10.23513 5.72507
  Smoking                9             0.809       −84.45%         0.303401       −2.551318 3.158121
  SBP                    9             0.149       25.96%          −0.06661       −.1639032 0.0306782
  blood glucose          8             0.879       −18.44%         −0.06317       −1.036518 0.9101708
  NIHSS score            10            0.194       24.96%          0.136064       −0.0853451 0.3574724
  Atrial fibrillation    10            0.054       46.30%          0.035621       −0.0008195 0.0720616
  Antiplatelet therapy   6             0.336       23.80%          −2.83066       −10.02345 4.362135
  Hyperlipidemia         7             0.159       35.21%          −0.01971       −0.0503131 0.0108966
  IV t-PA in EVT group   11            0.069       31.45%          0.008095       −0.0007779 0.0169683
  Use of solitaire FR    11            0.011       72.21%          0.008819       0.002606 0.0150324
  ASPECT\>7              8             0.081       58.50%          1.951249       −.3266271 4.229126
  Site of occlusion                                                               
  ICA                    9             0.197       100.00%         2.40161        −1.586371 6.389591
  M1                     9             0.309       100.00%         −1.40447       −4.429593 1.620653
  M2                     9             0.886       −102.77%        0.381309       −7.922869 8.369425
  Time from onset to                                                              
  t-PA                   10            0.122       33.04%          −0.00968       −0.0225864 0.0032263
  Randomization          8             0.227       26.75%          0.008191       −0.0066995 0.0230816
  groin puncture         7             0.631       −12.72%         0.004661       −0.0187709 0.028093
  reperfusion            5             0.265       \_              −0.00351       −0.0116583 0.0046468

NIHSS: National Institutes of Health Stroke Scale; SBP: systolic blood pressure; ICA: internal carotid artery; M1: M1 segment of Middle Cerebral Artery; M2: M2 segment of Middle Cerebral Artery; EVT: endovascular treatment t-PA: intravenous thrombolysis with tissue plasminogen activator; ASPECT: The Alberta Stroke Program Early Computed Tomography Score.

![Subgroup analysis of primary outcomes (mRS 0--2 at 90 days)\
(**A**) low (\< 60%) vs high (≥ 60%) rate of using Solitaire FR, (**B**) low (\< 50%) and high (≥ 50%) percentage of patients with hyperlipidemia, (**C**) low (\< 35%) vs high (≥ 35%) percentage of patients with atrial fibrillation.](oncotarget-08-72972-g003){#F3}

![Meta-regression analysis of relative factors affecting the favorable functional outcomes](oncotarget-08-72972-g004){#F4}

Quality of the included studies {#s2_5}
-------------------------------

Publication bias was assessed by Egger\'s test (*P* = 0.256) and Begg\'s funnel plot analysis with pseudo 95% confidence limits (Figure [6](#F6){ref-type="fig"}), the result showed no risk. Concrete data about the risk of bias of each studies were shown in Figure [5](#F5){ref-type="fig"}. Though all studies were unblinding of participants and personnel to treatment allocation. We still consider the selection and performance bias as unclear risk of bias, since by study design blinding is impossible (PROBE design)

![Risk of bias\
Review of the authors' judgment about each risk of bias item for each included study based on the criteria recommended by the Cochrane Collaboration for randomized controlled trials.](oncotarget-08-72972-g005){#F5}

![Funnel plot of included studies\
Funnel plot demonstrates possible evidence for publication bias in small studies, but larger studies show a symmetrical distribution of effects.](oncotarget-08-72972-g006){#F6}

DISCUSSION {#s3}
==========

This meta-analysis including 11 multicenter RCTs to evaluate the efficacy of EVT compared to standard medical therapy alone for patients with ischemic stroke. Our study indicated that EVT group was associated with high rates of favorable functional outcomeat 90 days and a favorable recanalization rate at 24 h when compared with medical care group. Nevertheless, no significant differences were observed in all-cause mortality at 90 days between EVT and standard medical care. Also, EVT was not associated with the high incidence rate of sICH at 90 days.

In our study, statistically considerable heterogeneity (*I*^2^ = 65.7%, *P* = 0.001) was found in favorable functional outcomes. Some factors could explain the discrepancy of different results between different RCTs. In the following RCTs, THERAPY 2016 \[[@R16]\], IMS III 2013 \[[@R14]\], MR RESCUE 2013 \[[@R15]\], and SYNTHESIS 2013 \[[@R8]\], the results showed similar safety outcomes and no significant difference in favorable functional outcomes with EVT, as compared with medical therapy alone. However, the subsequent RCTs, EXTEND-IA 2015 \[[@R17]\], MR CLEAN 2015 \[[@R18]\], SWIFT PRIME 2015 \[[@R19]\], REVASCAT 2015 \[[@R20]\], ESCAPE 2015 \[[@R21]\], THRACE 2016 \[[@R13]\], PISTE 2017 \[[@R22]\], were associated with high rates of functional independence. Such findings could be attributed to three considerable flaws of 4 former RCTs. In these RCTs (IMS III 2013, MR RESCUE 2013, SYNTHESIS 2013 and THERAPY 2016), intra-arterial t-PA or first-generation mechanical thrombectomy devices played a primary role in EVT. Such treatment may result in poor efficiency and related complications of EVT \[[@R11], [@R25]\]. Similarly, because of the different inclusion criteria, these trials selected patients without imaging evidence of large vessel occlusion, which would lead to the enrollment of patients with distal or no artery occlusion. Moreover, irregular use of IV t-PA in EVT group, especially in SYNTHESIS 2013 (0%) and MR RESCUE (43.8%), may be another non-negligible factor of the heterogeneity in our meta-analysis. The subsequent trials (EXTENT-IA 2015, MR CLEAN 2015, SWIFT PRIME 2015, REVASCAT 2015, ESCAPE 2015, THRACE 2016, PISTE 2017) ameliorated these limitations. In these recent 7 trials, patients were included with the confirmation of large vessel occlusion, and the rate of use of IV t-PA was high (at least 77.7% in IVT group, 68% in EVT group). The rate of employing thrombectomy devices in EVT group was up to at least 68% in trials after 2015 ([Supplementary Table 1](#SD1){ref-type="supplementary-material"}). Meanwhile, these trials used the newer generation device solitaire FR in \> 60% of cases in patients with thrombectomy ([Supplementary Table 2](#SD1){ref-type="supplementary-material"}). The solitaire FR Device achieved higher recanalization rates based on angiographic evidence, and also better neurological outcomes when compared with the Merci Retrieval System \[[@R11]\], the first proven device approved by FDA.

Actually, the above-mentioned 3 factors have been detailedly investigated in recent meta-analysis \[[@R4], [@R23], [@R24]\]. Hence, we attempted to implement the univariate meta-regression to identify the potential factors which were missed previously (Because of the limitation of numbers of RCTs, we chose univariate meta-regression instead of multi-factor regression). In our research, the univariate meta-regression indicated that the rate of using solitaire FR (*P* = 0.011, Adj R-squared = 72.21%) was associated with the heterogeneity of our study. Subgroup analysis indicated that patients with high use rate (\>= 60%) of solitaire FR in the EVT group had favorable functional outcomes compared with standard medical care alone (OR, 2.14; 95% CI, 1.75--2.61; *P* \< 0.001; Figure [3A](#F3){ref-type="fig"}). Such results further confirmed the influence of the significant flaws in 2013 RCTs, and suggested that the rate of using solitaire FR was the predominant influence factor behind the heterogeneity. Furthermore, two newfound factors, hyperlipidemia and atrial fibrillation, caught our attention (Figure [4B--4C](#F4){ref-type="fig"}). These two factors had never been reported in recent meta-analysis \[[@R4], [@R23], [@R24]\]. In the subgroup with a high percentage (\>= 35%) of stroke patients with atrial fibrillation, EVT showed an increased effectiveness (OR, 2.40; 95% CI, 1.81--3.19; P \< 0.001; Figure [3C](#F3){ref-type="fig"}). On the contrary, hyperlipidemia showed a negative correlation with the favorable functional outcomes (Figure [4B](#F4){ref-type="fig"}). In the subgroup with low percentage (\< 50%) of patients with hyperlipidemia, EVT also demonstrated an improving tendency in favorable functional outcomes (OR, 2.34; 95% CI, 1.80--3.04; P \< 0.001; Figure [3B](#F3){ref-type="fig"}). This phenomenon may have some plausible explanations.

Stroke of arterial origin can arise from cardioembolism, large artery atherosclerosis and small vessel disease (SVD) \[[@R26]\]. Hyperlipidemia is one of the major risk factors of stroke \[[@R27]\], and is thought to be strongly related to the diagnosis of SVD \[[@R28]\]. SVD is the most frequent pathological processes affecting small vessels and capillaries of the brain and play a crucial role in stroke. As an expression of SVD, lacunar stroke is associated with an excess risk of disability and death \[[@R29]\]. Apparently, patients with SVD can hardly obtain benefits from mechanical thrombectomy. However, IV t-PA is still a useful treatment for lacunar stroke, like the other stroke subtypes \[[@R30]\]. These reasons lead to the significant difference in the subgroup analysis which stratified the trials into low (\< 50%) and high (\>= 50%) percentage of patients with hyperlipidemia (Figure [3](#F3){ref-type="fig"}). Meanwhile, in subgroup with high rate (\>= 50%) of patients with hyperlipidemia, two of these 3 RCTs selected patients without imaging evidence of large vessel occlusion at the beginning of the trials (Figure [3](#F3){ref-type="fig"}, Table [1](#T1){ref-type="table"}). It likely leads to the enrollment of patients with SVD.

In subgroup with a high percentage (\>= 35%) of patients with atrial fibrillation, EVT was associated with increased effectiveness (Figure [3C](#F3){ref-type="fig"}, Figure [4C](#F4){ref-type="fig"}). Indeed, atrial fibrillation is the crucial cause of cardioembolic stroke (CES) which accounts for 1/5 incidence of ischemic stroke \[[@R31], [@R32]\], Meanwhile, atrial fibrillation-related (AF-related) stroke is thought to be linked to a worse 90-days outcomes when compared with other CES subtypes \[[@R32]\]. Ischemic stroke patients with AF can hardly benefit from intravenous thrombolysis when compare with non-AF patients \[[@R33], [@R34]\]. Hence, we speculated that the embolus type may be a potential influence factor affecting the recanalization rate and functional outcomes. Patients with AF-related CES can hardly gain benefits from IV t-PA \[[@R32]\]. But they can benefit from mechanical thrombectomy. This speculation is consistent with our analysis results (Figures [3](#F3){ref-type="fig"}, [4](#F4){ref-type="fig"}). A recent study suggested that mechanical thrombectomy can significantly improve the short- and long-term clinical outcomes of patients with cardioembolic stroke when compared with IV t-PA \[[@R35]\]. This result further corroborated our conjecture.

Limitation {#s3_1}
----------

There are numbers of limitations in our meta-analysis. Although mechanical thrombectomy plays an important role in the treatment of EVT, we can\'t ignore the influence of chemical thrombolytic treatment such as intra-arterial t-PA. Furthermore, we didn\'t include some factors into the univariate meta-regression because of insufficient data (imaging location, time from onset to imaging, congestive heart failure, coronary artery disease and so on). These missing data may lead to the neglect of other potential important factors. Moreover, due to the limited data, we could only conduct a simple stratified analysis to study the impact of hyperlipidemia and atrial fibrillation. A quantitative analysis should be done to determine the influence of different levels of blood lipids. Likewise, diverse types of atrial fibrillation are related to different long-term outcomes in patients with stroke \[[@R36]\]. Hence, it\'s of value to explore the individual treatment to ischemic stroke patients with diverse types of atrial fibrillation.

MATERIALS AND METHODS {#s4}
=====================

This meta-analysis was reported following the *Preferred Reporting Items for Systematic Reviews and Meta-Analyses* (PRISMA) guidelines \[[@R37]\].

Search method {#s4_1}
-------------

The investigators searched for studies published between January 2011 and April 2017 using several databases (PubMed, web of science, Cochrane Central Register of Controlled Trials). The search terms included "mechanical thrombolysis", "thrombectomy", "mechanical thrombectomy", "endovascular therapy", "embolectomy", "endovascular treatment", "endovascular thrombectomy" AND "Stroke", "acute ischemic stroke", "ischemic stroke", "cerebrovascular accident", AND "randomized controlled trial". The references of eligible articles were also selected in case of the omissions of RCTs.

Eligibility criteria {#s4_2}
--------------------

RCTs comparing EVT (t-PA with adjunctive embolectomy, mechanical thrombectomy alone or intra-arterial thrombolysis) with standard medical care alone were included in our study. Meanwhile, these eligible studies had to report the mRS and mortality at 90 days of patients \>18 years with AIS. In addition, mechanical thrombectomy must be part of the EVT and patients should be treated with intravenous t-PA in control group. Moreover, we excluded RCTs in which the number of participants was \< 20 or the follow-up was less than 90 day.

Selection of studies {#s4_3}
--------------------

Two reviewers (Z.J.W. and Z.N.N.) independently screened the titles and abstracts of the studies. Then the full texts would be assessed if the article passed the initial screening. Disagreements were solved by discussion or with the help of two other reviewers (S.L.G. and X.W.L.)

Data extraction {#s4_4}
---------------

Two reviewers (S.L.G. and Z.J.W.) independently extracted data from the eligible studies and supplementary materials. We used a standardized data extraction form to collect the following data: Characteristics of eligible studies (trial name, regions, number of centers, phases, publications, inclusion criteria, exclusion criteria, study design, efficacy outcome, safety outcome); Characteristics of patients (population, sex ratio, National Institutes of Health Stroke Scale (NIHSS), Alberta Stroke Program Early Computed Tomography Score (ASPECTS), time from onset to imaging, time from onset to intravenous thrombolysis, time from onset to randomization, time from onset to thrombectomy, Occlusion site, et al.). Two reviewers (X.W.L. and L.F.) independently evaluated any controversial data, and reconfirmed the extracted data.

Outcome measures and quality assessment {#s4_5}
---------------------------------------

The primary outcome was the number of patients with favorable functional outcomes (mRS 0--2) at 90 days. The secondary outcomes included recanalization rate at 24 h, all-cause mortality at 90 days and incidence rate of sICH at 90 days. In addition, we also evaluated whether the types of thrombectomy devices or the characteristics of patients (atrial fibrillation, hyperlipidemia) would affect the clinical outcomes leading to heterogeneity. According to the results of univariate meta-regression, we set the relevant cut-off values that could distinctly affect the effectiveness of EVT or IV t-pA (Figure [4](#F4){ref-type="fig"}), and the heterogeneity may also be decreased in the subsequent subgroup analysis \[[@R38], [@R39]\]. Thus, we stratified the included trials into low (\< 50%) and high (≥ 50%) percentage of patients with hyperlipidemia, low (\< 35%) vs high (≥ 35%) percentage of patients with atrial fibrillation and low (\< 60%) vs high (≥ 60%) rate of using Solitaire FR (Figure [3](#F3){ref-type="fig"}).

Biases of the included RCTs were assessed independently by 2 investigators (Z.J.W. and S.L.G.) using the Cochrane Collaboration risk of bias tool \[[@R28]\]. The items contained selection bias, performance bias, detection bias, attrition bias, reporting bias, and other potential biases. Each items was categorized as high, low, or unclear risks.

Statistical analysis {#s4_6}
--------------------

In our study, all outcomes were conducted by using the STATA 12 with a random effect model because of the possible heterogeneity. The heterogeneity among studies was measured by *I*^2^ value (low: \< 25%, moderate: 25%-70%, high: \> 70%) \[[@R40]\]. Univariate meta-regression (mixed-effects restricted maximum likelihood models) was used to find out the potential factors which could account for the heterogeneity. We collected the summary data of baseline patient characteristics ([Supplementary Table 3](#SD1){ref-type="supplementary-material"}) without selective elimination, and then deleted the variables which were reported in less than 4 RCTs (insufficient data may lead to the invalidity of meta-regression). The remaining variables which act as the covariates would participate in the process of meta-regression. Adjusted R square was the crucial index for us to find the heterogeneity, it represented the proportion of between-study variance explained by the covariates \[[@R41]\]. Variables with ideal Adjusted R square would get further processing. Subgroup analysis was used to further confirm the influence of these factors. The primary and secondary outcomes were measured by odds ratios (ORs) with corresponding 95% confidence intervals. The Cochrane collaboration\'s tool was used to estimate the risk of bias with RCTs. Meanwhile, Begg\'s funnel plot analysis was used to assess for publication bias.

CONCLUSIONS {#s5}
===========

EVT was associated with favorable functional outcomes and higher recanalization rate with imaging evidence compared with standard medical care alone. The incidence of symptomatic intracranial hemorrhage and mortality were similar among patients with EVT or IVT. The rate of using the new generation thrombectomy device was the most important factor influencing the effectiveness of EVT. Furthermore, hyperlipidemia and atrial fibrillation may be potential factors affecting therapy outcomes.

SUPPLEMENTARY MATERIALS TABLES {#s6}
==============================
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